 The Indian Council of Medical Research (ICMR) has invited Expression of Interest (EoI) from eligible organizations, companies, and manufacturers for the transfer of technology related to a new malaria vaccine ‘AdFalciVax’.
The recombinant chimeric multi-stage vaccine is designed to protect humans from plasmodium falciparum infection, the deadliest form of malaria, and aims to reduce its transmission at the community level.
ICMR will collaborate with selected partners to enable the large-scale commercialization and public availability of AdFalciVax, following a thorough evaluation of submissions based on defined criteria.
Interested parties can access the EoI document, which outlines the scope, qualification requirements, and submission procedures, from the official ICMR website. The deadline for submissions is August 17, 2025.
Applicants must submit their EoI through the Medical Innovation Patent Mitra portal (https://patentmitra.icmr.org.in/companyeoiregistration/).
ICMR-Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB) one of the constituent institutes of the Indian Council of Medical Research (ICMR), New Delhi has led development of a technology entitled “A recombinant chimeric multi-stage malaria vaccine (AdFalciVax) against plasmodium falciparum” consisting of full-length PfCSP (a pre-erythrocytic target for preventing infections in humans) in fusion with PfsPro6C (constituted of subdomains from two transmission blocking antigens Pfs230 and Pfs48/45).
ICMR-RMRCBB has technical-know-how of process to produce this recombinant chimeric multi-stage malaria vaccine in Lactococcus lactis thereof” (hereinafter) referred to as “Technology”. The pre-clinical validation of this technology has been conducted in collaboration with ICMR-National Institute of Malaria Research (ICMR-NIMR), another constituent institutes of ICMR and National Institute of Immunology (NII), New Delhi, an autonomous research institute of the Department of Biotechnology, Government of India.
ICMR- RMRCBB will provide expert guidance & technical support for the production of the vaccine in all the phases. This would accelerate the development of the Product and its commercialization.
ICMR would provide technical support through its team of experienced scientists in study planning, product development, development of study protocol, results/data analysis, outcome assessment, safety & efficacy assessment, product improvement, etc., if deemed fit upon the mutual understanding between ICMR and collaborative company.
ICMR through its Institutes would provide support and facilitation to conduct the R&D/clinical study of new technology/ product in India through its Affiliates/Institutes, in collaboration with the company/institutions. It would provide technical support in development of technology/ product and will also facilitate the validation, if required, as per the terms & conditions of the Agreement. ICMR shall have no financial implications unless otherwise specified.
As per the guidelines of EoI, the company shall have valid provisions to provide all necessary infrastructure/ material/ manpower required for product development/ validation/ scale-up either directly or otherwise. It shall have provisions to undertake the scale-up as required, manufacturing and commercialization of the vaccine.
The company shall also share the technical data with ICMR and participate in all discussions in a professional and mutually agreed-upon manner. It shall allow authorized personnel/scientist/team of ICMR to visit the designated lab/production facility as and when required, as envisaged under this EoI and subsequent Agreement.
The company shall be responsible for obtaining all the regulatory approvals required for commercialization or starting from R&D for product development to its commercialization.
|